Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Clinical Trials
1.5k
Trial Phases
5 Phases
Drug Approvals
70
Drug Approvals
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next
Clinical Trials
Distribution across different clinical trial phases (1410 trials with phase data)• Click on a phase to view related trials
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- First Posted Date
- 2025-09-22
- Last Posted Date
- 2025-09-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 980
- Registration Number
- NCT07184931
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- Conditions
- Ulcerative Colitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-09-22
- Last Posted Date
- 2025-09-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 980
- Registration Number
- NCT07184996
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- First Posted Date
- 2025-09-22
- Last Posted Date
- 2025-09-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 671
- Registration Number
- NCT07184944
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- Conditions
- Ulcerative Colitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-09-22
- Last Posted Date
- 2025-09-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 671
- Registration Number
- NCT07185009
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-09-12
- Last Posted Date
- 2025-09-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 188
- Registration Number
- NCT07170917
- Prev
- 1
- 2
- 3
- 4
- 5
- 297
- Next
News
Advanced Drug Delivery Technologies Drive Biotech Innovation as Nanomedicine Market Approaches $430 Billion
The global nanomedicine market is projected to grow from approximately $245 billion in 2023 to over $430 billion by 2028, driven by increasing adoption in oncology, neurology, and regenerative medicine.
Innate Pharma Advances Key Pipeline Assets While Implementing Strategic Restructuring
Innate Pharma received FDA Breakthrough Therapy Designation for lacutamab in Sézary syndrome and is nearing completion of Phase 3 trial protocol preparation following regulatory discussions.
AllRock Bio Secures $50 Million Series A to Advance First-in-Class Pan-ROCK Inhibitor for Pulmonary Hypertension
AllRock Bio raised $50 million in Series A funding co-led by Versant Ventures and Westlake BioPartners to advance ROC-101, a first-in-class oral pan-ROCK inhibitor exclusively licensed from Sanofi.
Enveda Biosciences Raises $150M Series D to Advance AI-Driven Drug Discovery Platform
Enveda Biosciences secured $150 million in Series D funding led by Premji Invest to advance its AI-powered drug discovery platform that mines natural molecules for therapeutic development.
Sanofi Shares Plummet 10% as Amlitelimab Phase III Data Falls Short of Dupixent Expectations
Sanofi's experimental atopic dermatitis drug amlitelimab met all primary endpoints in Phase III trials but showed weaker efficacy compared to the company's blockbuster drug Dupixent.
ArcaScience Secures $7M to Accelerate AI-Driven Drug Safety Evaluation Platform
ArcaScience raised $7 million in seed funding to expand its AI platform that transforms drug benefit-risk assessments from months-long processes to seconds-long computations.
Sanofi's Wayrilz Becomes First BTK Inhibitor Approved for Immune Thrombocytopenia Treatment
The FDA approved Wayrilz (rilzabrutinib) as the first BTK inhibitor for adults with persistent or chronic immune thrombocytopenia who have insufficient response to prior treatments.
Controlled Release Drug Delivery Market Expands with Major Pharma Investment in Precision Medicine Technologies
Major pharmaceutical companies including AbbVie, AstraZeneca, and Merck are actively developing controlled drug release systems to enhance treatment of chronic diseases, cancer, and neurological disorders.
Merck KGaA Partners with Skyhawk Therapeutics in $2 Billion RNA Splicing Collaboration for Neurological Disorders
Merck KGaA, Darmstadt, Germany has entered a strategic collaboration with Skyhawk Therapeutics valued at over $2 billion to discover novel RNA-targeting small molecules for neurological disorders with high unmet medical need.
Major Pharma M&A Surge and Landmark Antitrust Rulings Shape 2025 Life Sciences Landscape
The first half of 2025 witnessed unprecedented M&A activity with major deals including Merck's $3.9 billion SpringWorks acquisition, Sanofi's $9.5 billion Blueprint Medicines purchase, and Johnson & Johnson's $14.6 billion Intra-Cellular Therapies acquisition.